重组干扰素α-2b治疗慢性非甲非乙型/丙型肝炎
Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis.
作者信息
De Conca V, Mesiti S, Vallarino E, Mornese A, Dodero M
机构信息
EO Ospedali Galliera, Genova, Italy.
出版信息
Gut. 1993;34(2 Suppl):S126. doi: 10.1136/gut.34.2_suppl.s126.
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. The response was maintained during four to six months, follow up in 41.4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects.
在一项针对60例非甲非乙/丙型（NANB/C）慢性肝炎患者的研究中，使用α-2b干扰素（300万单位，持续六个月）治疗后，70.7%患者的丙氨酸转氨酶（ALT）活性恢复正常，29.3%患者无反应。41.4%患者在随访的四至六个月期间反应持续。肝脏活检标本显示，所有接受调查的患者组织学均有改善。治疗耐受性良好，仅出现轻微副作用。
Zotero 插件